Literature DB >> 27992217

Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis.

Donald A Patrick1, J Robert Gillespie, Joshua McQueen, Matthew A Hulverson, Ranae M Ranade, Sharon A Creason, Zackary M Herbst, Michael H Gelb, Frederick S Buckner, Richard R Tidwell1.   

Abstract

A previous publication from this lab (Patrick, et al. Bioorg. Med. Chem. 2016, 24 , 2451 - 2465 ) explored the antitrypanosomal activities of novel derivatives of 2-(2-benzamido)ethyl-4-phenylthiazole (1), which had been identified as a hit against n class="Species">Trypanosoma brucei, the causative agent of human African trypanosomiasis. While a number of these compounds, particularly the urea analogues, were quite potent, these molecules as a whole exhibited poor metabolic stability. The present work describes the synthesis of 65 new analogues arising from medicinal chemistry optimization at different sites on the molecule. The most promising compounds were the urea derivatives of 2-aryl-benzothiazol-5-amines. One such analogue, (S)-2-(3,4-difluorophenyl)-5-(3-fluoro-N-pyrrolidylamido)benzothiazole (57) was chosen for in vivo efficacy studies based upon in vitro activity, metabolic stability, and brain penetration. This compound attained 5/5 cures in murine models of both early and late stage human African trypanosomiasis, representing a new lead for the development of drugs to combat this neglected disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27992217      PMCID: PMC5362113          DOI: 10.1021/acs.jmedchem.6b01163

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice.

Authors:  Sayaka Shibata; J Robert Gillespie; Angela M Kelley; Alberto J Napuli; Zhongsheng Zhang; Kuzma V Kovzun; Ranae M Pefley; Jocelyn Lam; Frank H Zucker; Wesley C Van Voorhis; Ethan A Merritt; Wim G J Hol; Christophe L M J Verlinde; Erkang Fan; Frederick S Buckner
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  The productivity crisis in pharmaceutical R&D.

Authors:  Fabio Pammolli; Laura Magazzini; Massimo Riccaboni
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 3.  Antiprotozoal compounds: state of the art and new developments.

Authors:  F Astelbauer; J Walochnik
Journal:  Int J Antimicrob Agents       Date:  2011-05-05       Impact factor: 5.283

4.  Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis.

Authors:  Hari Babu Tatipaka; J Robert Gillespie; Arnab K Chatterjee; Neil R Norcross; Matthew A Hulverson; Ranae M Ranade; Pendem Nagendar; Sharon A Creason; Joshua McQueen; Nicole A Duster; Advait Nagle; Frantisek Supek; Valentina Molteni; Tanja Wenzler; Reto Brun; Richard Glynne; Frederick S Buckner; Michael H Gelb
Journal:  J Med Chem       Date:  2014-01-15       Impact factor: 7.446

5.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.

Authors:  B Räz; M Iten; Y Grether-Bühler; R Kaminsky; R Brun
Journal:  Acta Trop       Date:  1997-11       Impact factor: 3.112

6.  Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides.

Authors:  Stephanie Russell; Raphaël Rahmani; Amy J Jones; Harriet L Newson; Kevin Neilde; Ignacio Cotillo; Marzieh Rahmani Khajouei; Lori Ferrins; Sana Qureishi; Nghi Nguyen; Maria S Martinez-Martinez; Donald F Weaver; Marcel Kaiser; Jennifer Riley; John Thomas; Manu De Rycker; Kevin D Read; Gavin R Flematti; Eileen Ryan; Scott Tanghe; Ana Rodriguez; Susan A Charman; Albane Kessler; Vicky M Avery; Jonathan B Baell; Matthew J Piggott
Journal:  J Med Chem       Date:  2016-09-19       Impact factor: 7.446

7.  O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection.

Authors:  John H Ansede; Mariappan Anbazhagan; Reto Brun; Judy D Easterbrook; James Edwin Hall; David W Boykin
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

8.  Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.

Authors:  Els Torreele; Bernadette Bourdin Trunz; David Tweats; Marcel Kaiser; Reto Brun; Guy Mazué; Michael A Bray; Bernard Pécoul
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21

9.  SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Authors:  Robert T Jacobs; Bakela Nare; Stephen A Wring; Matthew D Orr; Daitao Chen; Jessica M Sligar; Matthew X Jenks; Robert A Noe; Tana S Bowling; Luke T Mercer; Cindy Rewerts; Eric Gaukel; Jennifer Owens; Robin Parham; Ryan Randolph; Beth Beaudet; Cyrus J Bacchi; Nigel Yarlett; Jacob J Plattner; Yvonne Freund; Charles Ding; Tsutomu Akama; Y-K Zhang; Reto Brun; Marcel Kaiser; Ivan Scandale; Robert Don
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

10.  Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign.

Authors:  Melissa L Sykes; Jonathan B Baell; Marcel Kaiser; Eric Chatelain; Sarah R Moawad; Danny Ganame; Jean-Robert Ioset; Vicky M Avery
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29
View more
  14 in total

Review 1.  Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.

Authors:  Shikha Kumari; Angelica V Carmona; Amit K Tiwari; Paul C Trippier
Journal:  J Med Chem       Date:  2020-08-04       Impact factor: 7.446

2.  New Class of Antitrypanosomal Agents Based on Imidazopyridines.

Authors:  Daniel G Silva; J Robert Gillespie; Ranae M Ranade; Zackary M Herbst; Uyen T T Nguyen; Frederick S Buckner; Carlos A Montanari; Michael H Gelb
Journal:  ACS Med Chem Lett       Date:  2017-06-27       Impact factor: 4.345

3.  Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  J Med Chem       Date:  2019-12-02       Impact factor: 7.446

Review 4.  Novel lead compounds in pre-clinical development against African sleeping sickness.

Authors:  Michael Berninger; Ines Schmidt; Alicia Ponte-Sucre; Ulrike Holzgrabe
Journal:  Medchemcomm       Date:  2017-07-31       Impact factor: 3.597

Review 5.  Current advances in the synthetic strategies of 2-arylbenzothiazole.

Authors:  Ayushi Sethiya; Nusrat Sahiba; Pankaj Teli; Jay Soni; Shikha Agarwal
Journal:  Mol Divers       Date:  2020-11-12       Impact factor: 2.943

6.  Early Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads.

Authors:  Michael H Gelb; Frederick S Buckner
Journal:  ACS Infect Dis       Date:  2021-04-19       Impact factor: 5.578

7.  A Fluorinated Phenylbenzothiazole Arrests the Trypanosoma cruzi Cell Cycle and Diminishes the Infection of Mammalian Host Cells.

Authors:  Roberto I Cuevas-Hernández; Richard M B M Girard; Sarai Martínez-Cerón; Marcelo Santos da Silva; Maria Carolina Elias; Marcell Crispim; José G Trujillo-Ferrara; Ariel Mariano Silber
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

8.  Selective N-Alkylation of Amines with DMC over Biogenic Cu-Zr Bimetallic Nanoparticles.

Authors:  Ashutosh Sharma; Khushboo Verma; Sandeep Kaushal; Rahul Badru
Journal:  ACS Omega       Date:  2021-06-07

9.  Anti-ulcerogenic and anti-ulcerative colitis (UC) activities of seven amines derivatives.

Authors:  Amani S Awaad; Ahmed M Alafeefy; Fatmah A S Alasmary; Reham M El-Meligy; Saleh I Alqasoumi
Journal:  Saudi Pharm J       Date:  2017-07-11       Impact factor: 4.330

Review 10.  Saturated Five-Membered Thiazolidines and Their Derivatives: From Synthesis to Biological Applications.

Authors:  Nusrat Sahiba; Ayushi Sethiya; Jay Soni; Dinesh K Agarwal; Shikha Agarwal
Journal:  Top Curr Chem (Cham)       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.